Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
Sponsor: Syntis Bio
Summary
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
Official title: A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2026-01-05
Completion Date
2026-12-31
Last Updated
2026-01-15
Healthy Volunteers
Yes
Conditions
Interventions
SYNT101
Tablet
Placebo
Placebo tablet to match SYNT101 in appearance.
Locations (1)
Veritus Research
Bayswater, Victoria, Australia